文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

皮下注射替尔泊肽对比安慰剂联合滴定甘精胰岛素对2型糖尿病患者血糖控制的影响:SURPASS-5随机临床试验

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

SURPASS-5随机3期试验在8国45个中心纳入475例甘精胰岛素±二甲双胍血糖控制不佳的2型糖尿病患者,随机接受替尔泊肽5、10、15 mg或安慰剂每周皮下注射40周。替尔泊肽各剂量组HbA1c降幅和体重降幅均显著大于安慰剂,HbA1c<7%达标率更高,最常见不良事件为腹泻和恶心。

要点

  • 替尔泊肽10 mg和15 mg组HbA1c降幅均显著大于安慰剂,差异分别为-1.53%和-1.47%。
  • 替尔泊肽5、10、15 mg组体重降幅均显著大于安慰剂,差异分别为-7.1、-9.1、-10.5 kg。
  • 替尔泊肽组HbA1c<7%达标率85%-90%,高于安慰剂组的34%,差异有统计学意义。

核心结论

  • 在甘精胰岛素治疗血糖控制不佳的2型糖尿病患者中,加用皮下替尔泊肽对比安慰剂联合滴定甘精胰岛素,40周时血糖控制获得统计学显著改善。

研究设计与样本

  • 随机3期临床试验,在8个国家45个医学研究中心和医院开展,入组时间2019年8月30日至2020年3月20日,随访于2021年1月13日完成。
  • 纳入475例接受每日一次甘精胰岛素±二甲双胍治疗但血糖控制不佳的成人2型糖尿病患者,按1:1:1:1随机分配。
  • 干预为每周一次皮下注射替尔泊肽5 mg(n=116)、10 mg(n=119)、15 mg(n=120)或体积匹配安慰剂(n=120),共40周;替尔泊肽起始2.5 mg/周,每4周递增2.5 mg直至达到指定剂量。
  • 475例随机化参与者中女性211例(44%),平均(SD)年龄60.6(9.9)岁,平均(SD)HbA1c 8.31%(0.85%),451例(94.9%)完成试验。

主要发现

  • 第40周HbA1c较基线平均变化:替尔泊肽10 mg组-2.40%、15 mg组-2.34%,安慰剂组-0.86%;10 mg组与安慰剂组差异-1.53%(97.5%CI -1.80%至-1.27%),15 mg组差异-1.47%(97.5%CI -1.75%至-1.20%),P均<.001。
  • 第40周HbA1c较基线平均变化:替尔泊肽5 mg组-2.11%,与安慰剂组差异-1.24%(95%CI -1.48%至-1.01%),P<.001。
  • 体重较基线平均变化:替尔泊肽5 mg组-5.4 kg、10 mg组-7.5 kg、15 mg组-8.8 kg,安慰剂组1.6 kg;与安慰剂组差异分别为5 mg组-7.1 kg(95%CI -8.7至-5.4)、10 mg组-9.1 kg(95%CI -10.7至-7.5)、15 mg组-10.5 kg(95%CI -12.1至-8.8),P均<.001。
  • HbA1c<7%的患者比例:替尔泊肽组85%-90%,安慰剂组34%,P均<.001。
  • 替尔泊肽组对比安慰剂组最常见的治疗中出现的不良事件为腹泻(12%-21% vs 10%)和恶心(13%-18% vs 3%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment of type 2 diabetes have not been described. OBJECTIVE: To assess the efficacy and safety of tirzepatide added to insulin glargine in patients with type 2 diabetes with inadequate glycemic control. DESIGN, SETTING, AND PARTICIPANTS: Randomized phase 3 clinical trial conducted at 45 medical research centers and hospitals in 8 countries (enrollment from August 30, 2019, to March 20, 2020; follow-up completed January 13, 2021) in 475 adults with type 2 diabetes and inadequate glycemic control while treated with once-daily insulin glargine with or without metformin. INTERVENTIONS: Patients were randomized in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of 5-mg (n = 116), 10-mg (n = 119), or 15-mg (n = 120) tirzepatide or volume-matched placebo (n = 120) over 40 weeks. Tirzepatide was initiated at 2.5 mg/week and escalated by 2.5 mg every 4 weeks until the assigned dose was achieved. MAIN OUTCOMES AND MEASURES: The primary end point was mean change from baseline in glycated hemoglobin A1c (HbA1c) at week 40. The 5 key secondary end points included mean change in body weight and percentage of patients achieving prespecified HbA1c levels. RESULTS: Among 475 randomized participants (211 [44%] women; mean [SD] age, 60.6 [9.9] years; mean [SD] HbA1c, 8.31% [0.85%]), 451 (94.9%) completed the trial. Treatment was prematurely discontinued by 10% of participants in the 5-mg tirzepatide group, 12% in the 10-mg tirzepatide group, 18% in the 15-mg tirzepatide group, and 3% in the placebo group. At week 40, mean HbA1c change from baseline was -2.40% with 10-mg tirzepatide and -2.34% with 15-mg tirzepatide vs -0.86% with placebo (10 mg: difference vs placebo, -1.53% [97.5% CI, -1.80% to -1.27%]; 15 mg: difference vs placebo, -1.47% [97.5% CI, -1.75% to -1.20%]; P < .001 for both). Mean HbA1c change from baseline was -2.11% with 5-mg tirzepatide (difference vs placebo, -1.24% [95% CI, -1.48% to -1.01%]; P < .001]). Mean body weight change from baseline was -5.4 kg with 5-mg tirzepatide, -7.5 kg with 10-mg tirzepatide, -8.8 kg with 15-mg tirzepatide and 1.6 kg with placebo (5 mg: difference, -7.1 kg [95% CI, -8.7 to -5.4]; 10 mg: difference, -9.1 kg [95% CI, -10.7 to -7.5]; 15 mg: difference, -10.5 kg [95% CI, -12.1 to -8.8]; P < .001 for all). Higher percentages of patients treated with tirzepatide vs those treated with placebo had HbA1c less than 7% (85%-90% vs 34%; P < .001 for all). The most common treatment-emergent adverse events in the tirzepatide groups vs placebo group were diarrhea (12%-21% vs 10%) and nausea (13%-18% vs 3%). CONCLUSIONS AND RELEVANCE: Among patients with type 2 diabetes and inadequate glycemic control despite treatment with insulin glargine, the addition of subcutaneous tirzepatide, compared with placebo, to titrated insulin glargine resulted in statistically significant improvements in glycemic control after 40 weeks. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04039503.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022. PMID: 35133415. doi:10.1001/jama.2022.0078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。